Uni-Pioneers BioMed

Uni-Pioneers is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of innovative therapies for autoimmune and inflammatory diseases. The company utilizes a dual-track approach, developing both high-affinity biologics, such as nanobodies, and potent small molecule inhibitors. Its lead program, UPB101, is a bispecific nanobody targeting both IL-17A and IL-17F, currently undergoing Phase 2 clinical evaluation for plaque psoriasis. Uni-Pioneers is supported by prominent venture capital firms and maintains a state-of-the-art research facility in the Zhangjiang Hi-Tech Park. The company's mission is to provide differentiated treatment solutions that improve the quality of life for patients with chronic inflammatory conditions.